|Year : 2009 | Volume
| Issue : 3 | Page : 297-303
|Approach to diagnosis of auto-immune hepatitis
Megha Joshi1, Urmila Khettry2
1 Department of Pathology, Lawrence General Hospital, Lawrence, USA
2 Tufts University School of Medicine, Department of Anatomic Pathology, Lahey Clinic Medical Center, Burlington, USA
Click here for correspondence address and email
|Date of Web Publication||12-Aug-2009|
| Abstract|| |
Auto-immune hepatitis (AIH) is one of the chronic liver diseases, seen predominantly in women, resulting from dysregulated immune mechanisms not yet clearly defined. Based on a combination of clinical and laboratory parameters with both positive and negative weights, the International AIH Group devised a scoring system in 1993. The system was modified in 1999 and has proven useful for both diagnostic and research purposes. This review deliberates on the clinical, immunological and histological features of this entity.
Keywords: Auto-antibodies, auto-immune diseases, chronic liver disease, hepatitis, liver biopsy
|How to cite this article:|
Joshi M, Khettry U. Approach to diagnosis of auto-immune hepatitis. Indian J Pathol Microbiol 2009;52:297-303
| Brief Summary and Objectives|| |
Auto-immune hepatitis (AIH) is one of the chronic liver diseases resulting from dysregulated immune mechanisms which are not yet clearly defined. The diagnosis is based on a constellation of clinical, serological, and histopathological findings. Clinically, it is more often encountered in women than men and may be seen in both adult and pediatric populations. Seropositivity for auto-antibodies is found in most cases. Histologically, the typical findings consist of periportal, portal, and lobular chronic inflammation with prominent plasma cells. Most AIH patients respond to immunosuppressive therapy. Liver transplantation is a valid treatment option for end-stage liver disease resulting from AIH as, in a transplanted liver, AIH may recur.
The objectives of this review are to:
- delineate the typical clinico-pathological findings of AIH
- define the subtypes of AIH
- identify the differential diagnostic issues
- describe the role of liver biopsy in the management of AIH patients
- emphasize the importance of a "correct" diagnosis
- discuss recurrence in transplanted liver
Auto-immune hepatitis is a chronic liver disorder seen predominantly in women and is associated with polyclonal hyper-gammaglobulinemia, and serologically demonstrable autoantibodies. ,, A characteristic immunogenetic phenotype consisting of HLA A1, B8, DR3 or DR4 is noted in a majority of cases. The establishment of the diagnosis of AIH mandates exclusion of other causes of chronic liver disease such as viral, alcohol, or drug-related hepatic injury. A favorable response to immunosuppressive therapy is usually seen and considered a "confirmatory clinical test."
Based on a combination of clinical and laboratory parameters with both positive and negative weights, the International Auto-immune Hepatitis Group devised a scoring system in 1993 [Table 1].  The sum of the numerical scores given to each of these parameters is useful in predicting the definite or possible diagnosis of AIH in a given patient. The system was modified in 1999 [Table 2] and has proven useful for both diagnostic and research purposes. It is highly sensitive for the diagnosis of AIH with a diagnostic accuracy close to 90%. The negative scores given to biliary markers/findings help in excluding AIH in patients with biliary diseases who may have some overlapping features.
Similar to other autoimmune disorders, AIH is also a manifestation of dysregulated immune reaction possibly of the suppressor T-cells.  Exact pathogenic mechanisms have, however, not yet been delineated. It is postulated that perhaps a peripheral break of tolerance against antigens expressed in the liver may induce an autoimmune response possibly in a genetically susceptible individual.  Auto-antibodies seen in patients with AIH do have an immense diagnostic importance, but their role, if any, in the pathogenesis of the disease, is not clear. However, it must be noted that some of the auto-antibodies seen in AIH patients may act against hepatocytic surface antigens or may be directed against molecules present on the myriads of enzyme systems present within the hepatocytes.
| Clinical Data|| |
Clinical presentation of AIH patients is variable. ,,, Elevated liver enzymes may be found on screening asymptomatic patients or those who seek medical attention for other conditions such as arthralgias, thyroid disease, and other disorders of putative autoimmune etiology., A few patients may have fulminant hepatic failure or rapidly progressive hepatitic disorder of recent onset. , Majority of the patients present with a chronic disease with lethargy or low-grade flu-like symptoms or even liver decompensation due to cirrhosis. 
Most cases of AIH are seen among Caucasian and Japanese population.  However, it is now being reported from other regions of the world, including India, due to increasing awareness and recognition of characteristic findings. ,, AIH is almost eight-fold more common in women as compared to men and is seen in pediatric population as well. The disease seen in children is often more rapidly progressive than that encountered in adult population. Although often not performed, testing for HLA phenotypes associated with AIH i.e., A1, B8, DR3 or DR4, provides important laboratory support for the diagnosis of AIH. 
Liver function tests in AIH are usually more ''hepatitic'' than ''cholestatic'' and reflected biochemically as elevation of transaminases rather than alkaline phosphatase or bilirubin. However, a completely normal profile may be seen during the quiescent periods interrupted by a severe hepatitic profile during the disease "flare-ups". Disease progression with the development of cirrhosis may be biochemically associated with elevated bilirubin and evidence of synthetic dysfunction.
Hypergammaglobulinemia with disproportionately increased IgG and serologic positivity for autoantibodies are the important defining features of AIH. ,, Auto-antibodies are not specific for AIH. However, their presence in the serum is of diagnostic importance and further help in categorizing the various subtypes of AIH. As a rule, auto-antibodies should not be used to monitor therapy, predict AIH activity or outcome.  Anti-nuclear antibodies (ANA) are encountered in about 80% of AIH patients in titers greater than 1:40 and anti-smooth muscle antibodies (ASMA) in titers greater than 1:40 are seen in approximately 70%. The ANA associated with AIH usually give a homogeneous pattern, due to reactivity against histones and DNA, but other patterns may be seen as well. , ASMA are directed against several cytoskeletal elements.  Both ANA and ASMA, in low titers, may be seen in other chronic liver diseases such as hepatitis C (HCV), Wilson disease, alcohol-related liver disease, or nonalcoholic steatohepatitis. ,,, A case of acute hepatitis E with serum ANA and ASMA positivity has also been reported.  Other auto-antibodies that may be seen in AIH include anti-liver kidney microsomal (anti-LKM), anti-soluble liver antigen (anti-SLA), anti-liver pancreas (anti-LP), anti-asialoglycoprotein (anti-ASGPR) antibodies, and also pANCA. ,,, The target protein for anti-LKM1 antibody is P450(CYP)2D6 and is seen in patients with DRB1*0701 allele.
Based on clinical and serological parameters, AIH cases have been categorized into three subtypes  Type I, Type II and Type III.
Type I is the most common form of the disease. Seen mostly in adult women serologically, it is characterized by the presence of high-titer ANA and/or ASMA; Typ e II, seen more frequently in the pediatric population, is often associated with severe clinical disease and positive anti-LKM in the serum and these patients are usually negative for ANA or ASMA. Type II AIH was earlier sub-classified into Type IIa that included patients with characteristics described before, and Type IIb representing HCV patients with low-titer anti-LKM in their sera. The latter category is now considered clinically irrelevant and these cases, with both anti-HCV and anti-LKM positivity, are viewed as essentially chronic hepatitis C with perhaps some autoimmune features. AIH patients with other autoantibodies, like anti-SLA, anti-LP, or anti-ASGPR, are categorized as Type III , but clinically, this group does not seem to have any particular distinctive characteristics. A case of IgG4-associated AIH with elevated serum IgG4 and IgG4-bearing plasma cells in the liver has been recently reported. 
Most patients with AIH respond to corticosteroids with or without azathioprine.  AIH-related cirrhosis [Figure 9] may develop despite proper therapy or when treatment is delayed for any reason. These patients presenting with late-stage disease may require liver transplantation. Recurrence of AIH in the allograft has been reported. ,
| Pathology|| |
A pathological diagnosis of AIH is usually made by observing compatible histopathological findings on a liver specimen.  A detailed knowledge of all available clinical and serologic findings is imperative for the pathologist interpreting these specimens. In addition to evaluating liver biopsies during the diagnostic work- up of AIH patients, pathologists' role in the management of AIH patients has expanded in recent years and now, also involves examination of explanted liver specimens from these patients undergoing liver transplantation (LT) and post-LT biopsies. ,
The gross findings present in explants from AIH patients are not very distinctive and mirror those seen in other chronic liver disorders. However, the gross characteristics do correlate with the clinical presentation and may range from being normal in early stages to obvious cirrhosis in long-standing progressive cases. Submassive and massive hepatic necrosis with parenchymal collapse is seen in patients who present with rapidly progressive or fulminant hepatic failure. Although hepato-cellular carcinoma can develop in any cirrhotic liver, their occurrence in AIH cirrhosis is highly unlikely.
Histologically, portal and periportal chronic inflammation [Figure 1] with prominent plasma cells [Figure 2] is typically seen on liver biopsies from patients with AIH. The amount of inflammation and number of plasma cells can be quite variable [Figure 5]. In clinically severe cases the periportal lymphoplasmacytic activity (interface hepatitis or piece-meal necrosis) may be very pronounced [Figure 3].  Presence of portal plasma cells in liver biopsies, from patients under therapy-induced remission, was found to be a predictor of relapse following treatment withdrawal. The necro-inflammatory process may involve the lobules too with scattered lymphoplasmacytic aggregates with single cell hepatocytic necrosis resulting in acidophil bodies may be present [Figure 4]. While pericentral chronic inflammation with prominent plasma cells is fairly frequently observed in cases with high grade of activity, this may be the only feature present in some cases that lack portal and periportal inflammation. It is possible that pericentral plasma cell rich chronic inflammation may be the earliest finding in some cases of AIH [Figure 6]. ,,, Severe lymphoplasmacytic necro-inflammation with bridging collapse is often seen in cases presenting clinically with a rapid onset course [Figure 7]. In severe or progressive cases, the hepatocytic regenerative changes following lobular injury may alter the cord pattern and foci of hepatocytic acinar transformation may be seen [Figure 8].
Since AIH is a chronic liver disease, all biopsy reports must include the grade of inflammation and stage of fibrosis. Many different validated scoring systems have been published and are available for use by pathologists involved in interpreting liver biopsies. ,, However, consistency in the grading and staging of chronic hepatitis at any given institution is highly recommended and the choice of system can be made following a joint consultation between the pathologist and clinicians.
Although, the earliest Knodell scoring system was being extensively used for numerous studies, the inclusion of the fibrosis score in the overall hepatitis activity index (HAI) seemed to be a drawback of that system. As a result, the severity of necro-inflammation and extent of fibrosis could not be distinctly delineated. This flaw of the system was corrected in Ishak's modification of the original HAI system by reporting separately the numerical scores for grading of necro-inflammation and staging of fibrosis. A much simpler, yet, quite useful schema was proposed by Batts and Ludwig. In their system, both the necro-inflammation and fibrosis are individually scored semiquantitatively on a scale of 0-4. The French METAVIR system is similar and grades necro-inflammation on a scale of 0-3 and stages fibrosis as 0-4. 
| Overlap Syndromes|| |
Some AIH patients may present with features that do not fit within the established criteria and in addition, have features of another putative immune mediated liver disorder such as, primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC). These patients can not be assigned to a single disease category and the term overlap syndrome is used to characterize them. ,,,,,, Clinical and histologic evidence of both disorders may be present simultaneously or may appear sequentially. In rare patients there may be a switch from one disease to the other. Although standardized diagnostic criteria have not yet been defined, the diagnosis of overlap syndrome mandates definite evidence of both a hepatitic and biliary disease complemented with complete evaluation of clinical, biochemical, immunologic, radiological and pathological findings. The diagnosis is of importance from a therapeutic standpoint, because both components of the syndrome must be considered before an optimal treatment can be tailored for each patient. PBC/AIH overlap syndrome is more common than PSC/AIH.
| Differential Diagnostic Issues|| |
Auto-antibody negative patients - Some AIH patients at their initial presentation may be negative for serum autoantibodies that are typically associated with that diagnosis. The establishment of the correct diagnosis of AIH may pose difficulties and is usually made on the basis of "hepatitic" serum biochemical abnormalities, characteristic microscopic findings, and HLA phenotypes. In addition, they may have other serum auto-antibodies such as p-ANCA or just elevated IgG levels. There may be other patients who persistently remain auto-antibody-negative and carry the diagnosis of cryptogenic hepatitis or cirrhosis. The possible autoimmune pathogenesis in some patients with cryptogenic liver disease is of therapeutic importance because they might benefit from immunosuppressive therapy. , Furthermore, if transplanted, the disease may recur in the liver allograft with features of AIH, causing significant differential diagnostic problems. 
Viral hepatitis - Low titer auto-antibodies may be seen in HBV or HCV patients. Viral markers are usually helpful in clarifying the diagnostic dilemma in most cases. However, a small percentage of HCV patients may indeed have concomitant AIH and pose considerable problems in devising a therapeutic strategy for them. While steroids may increase viral replication, interferon therapy for HCV may be associated with a strong autoimmune type inflammatory response.  Since pANCA is rare in chronic viral hepatitis it may be of use in such clinical circumstances to diagnose concomitant AIH.
Drug induced or toxic hepatitis - Some drugs or toxins may elicit an autoimmune reaction or mimic liver biopsy findings seen in AIH. ,, As with any drug or toxin, withdrawal of the particular agent ("drug holiday") should, in most cases, resolve the hepatic disorder.
Importance of liver biopsy
Liver biopsy plays an important role in management of AIH patients. It provides the clinicians with information regarding the following four issues - Pathological findings compatible with AIH diagnosis Grade of necro-inflammatory activity Stage of fibrosis Response to therapy
Diagnostic approach to AIH
The following factors must be taken into consideration by both the clinician and pathologist during the evaluation of patients with the possible diagnosis of AIH.
Recurrence in transplanted liver
- Consider as a cause of liver disease in both adult and pediatric population
- Consider as a cause of liver disease regardless of clinical presentation: fulminant, rapid-onset, or chronic
- Consider some of the demographic findings: female gender, both in pediatric and adult population Obtain serologic studies for auto-antibodies
- Exclude other causes of liver disease by history (including "drug holiday"), biochemical, radiologic, serologic, and molecular studies.
- Consider the confounding issues in HCV patients.
- Correlate with liver biopsy findings: a) portal and periportal inflammation with prominent plasma cells, b) grade and stage.
- If available, correlate with the HLA subtypes.
- Response to steroids or other immunosuppressive therapy.
- Consider overlap syndrome in atypical cases.
AIH can recur following liver transplantation and may pose significant differential diagnostic problems. The scoring system devised by the International AIH Study Group is generally of limited value in a transplant setting, given the multitude of other causes of graft dysfunction with overlapping features. A diagnosis of recurrent AIH mandates optimal clinicopathological and serological correlation and expert review of biopsies.
A syndrome of de novo AIH is seen in liver transplant recipients who receive hepatic allograft for diseases other than AIH. , A correct diagnosis, albeit difficult, is of utmost clinical importance for optimal therapeutic strategy.
| Summary and Conclusions|| |
AIH is an a priori chronic liver disease and is diagnosed based on a combination of clinical, serologic and histological findings.
AIH patients respond favorably to immunosuppressive therapy.
Exclusion of other forms of hepatitis is important for therapeutic reasons.
| References|| |
|1.||McFarlane IG. Autoimmune hepatitis: Diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002;6:317-33. |
|2.||Manns MP, Strassburg CP. Autoimmune hepatitis: c0 linical challenges. Gastroenterol 2001;120:1502-17. |
|3.||McFarlane IG. Definition and classification of autoimmune hepatitis. Semin Liver Dis 2002;22:317-24. [PUBMED] [FULLTEXT]|
|4.||Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis study Group. Hepatology 1993;18:998-1005. [PUBMED] |
|5.||Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatology 1999;31:929- 38. |
|6.||Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31. [PUBMED] [FULLTEXT]|
|7.||Lapierre P, Beland K, Alvarez F. Pathogenesis of autoimmune hepatitis: f0 rom break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007;149:107-13. |
|8.||Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000;32:181-97. [PUBMED] |
|9.||Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Minerva Gastroenterol Dietol 2004;50:113-23. [PUBMED] |
|10.||Thiele DL. Autoimmune hepatitis. Clin Liver Dis 2005;9:635-46. [PUBMED] |
|11.||Luxon BA. Autoimmunehepatitis. Making sense of all those antibodies. Postgrad Med 2003;114:79-82. |
|12.||Cronin EM, Sibartie V, Crosbie OM, Quigley EM. Autoimmune hepatitis in association with lymphocytic colitis. J Clin Gastroenterol 2006;40:648-50. [PUBMED] [FULLTEXT]|
|13.||Oki K, Yamane K, Koide J, Mandai K, Nakanishi S, Fujikawa R, Kohno N. A case of polyglandular autoimmune syndrome type III complicated with autoimmune hepatitis. Endocr J 2006;53:705-9. [PUBMED] [FULLTEXT]|
|14.||Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19:699-708. |
|15.||Tokumoto Y, Onji M. Acute-onset autoimmune hepatitis. Intern Med 2007;46:1-2. [PUBMED] [FULLTEXT]|
|16.||Verma S, Gunuwan B, Mendler M, Govindrajan S, Redekar A. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: r0 ole of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99:1510-6. |
|17.||Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002;6:347-59. |
|18.||Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent; 7 years experience. J Gastroenterol Hepatol 2001;16: 1144-8. [PUBMED] [FULLTEXT]|
|19.||Gohar S, Desai D, Joshi A, Bhaduri A, Deshpande R, Balkrishna C, et al . Autoimmune hepatitis: a0 study of 50 patients. Indian J Gastroenterol 2003;22:140-2. [PUBMED] |
|20.||Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: Profile of an uncommon disease. BMC Gastroenterol 2005;5:27. [PUBMED] [FULLTEXT]|
|21.||Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9. [PUBMED] [FULLTEXT]|
|22.||Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: i0 mportant tools in clinical practice and to study pathogenesis of the disease. Autoimmune Dis 2004;1:2. |
|23.||Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target auroantigens in autoimmune hepatitis: a0 n overview. Eur J Intern Med 2002;13:293-303. [PUBMED] [FULLTEXT]|
|24.||Czaja AJ, Homburger. Autoantibodies in liver disease. Gastroenterol 2001;120:239-49. |
|25.||Chen M, Shirai M, Czaja AJ, Kurokohchi K, Arichi T, Arima K, et al . Characterisation of anti-histone antibodies in patients with type1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;199:483-9. |
|26.||Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of immunofluorescence in type1 autoimmune hepatitis. Dig Dis Sci 1997;42:1688-96. [PUBMED] [FULLTEXT]|
|27.||Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significant of antibodies to actin in type1 autoimmune hepatitis. Hepatology 1996;24:1068-73. [PUBMED] [FULLTEXT]|
|28.||Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune hepatitis: a comparative analysis. Hepatology 1992;15:572-77. [PUBMED] |
|29.||Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99:1316-20. |
|30.||Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al . Serum autoantibodies in chronic hepatitis C: c0 omparison with autoimmune hepatitis and and impact on disease profile. Hepatology 1997;26:561-6. |
|31.||Wozniak M, Socha P. Two cases of Wilson disease diagnosed as autoimmune hepatitis (in Polish). Przegl Epidemiol 2002;56:22-5. |
|32.||Nagasaki F, Ueno Y, Mano Y, Igarashi T, Yahagi K, Niitsuma H, et al . A patient with clinical features of acute hepatitis E viral infection with autoimmune hepatitis. Tohoku J Exp Med 2005;206:173-9. [PUBMED] [FULLTEXT]|
|33.||Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterol 1995;108:1159-66. |
|34.||Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, et al . Anti-neutrophil cytoplasmic antibodies in type1 and 2 autoimmune hepatitis. Hepatology 1997;25:1105-7. [PUBMED] [FULLTEXT]|
|35.||Treichel U, McFarlane BM, Seki T, Krawitt EL, Alessi N, Stickel F, et al . Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterol 1994;107:799-804. |
|36.||Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993;105:1522-8. [PUBMED] |
|37.||Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98. [PUBMED] [FULLTEXT]|
|38.||Umemura T, Zen Y, Hamano H, Ichijo T, Kawa S, Nakanuma Y, et al . IgG4-associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis. Gut 2007;56:1471-2. [PUBMED] [FULLTEXT]|
|39.||Czaja A, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97. |
|40.||Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al . Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000;32:185-92. [PUBMED] [FULLTEXT]|
|41.||Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al . Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7:302-10. |
|42.||Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6:397-417. |
|43.||Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawl in type 1 autoimmune hepatitis. Liver Int 2003;23:116-23. [PUBMED] [FULLTEXT]|
|44.||Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113:664-8. [PUBMED] [FULLTEXT]|
|45.||Abraham SC, Burgart LJ. Isolated centrilobular hepatitis: a distinctive histologic lesion with several clinicopathologic associations. Modern Pathology 2004;17 S1:294A. |
|46.||Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004;28:471-8. [PUBMED] [FULLTEXT]|
|47.||Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59:246-9. [PUBMED] [FULLTEXT]|
|48.||Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, staging and grading. Hepatology 1994;19:1513-20. [PUBMED] |
|49.||Ishak KG, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9. |
|50.||Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. AM J Surg Pathol 1995;19: 1409-17. |
|51.||Bedossa P, Poynard T. The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93. |
|52.||Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology 2001;33:994-1002. [PUBMED] [FULLTEXT]|
|53.||Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, et al . Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune hepatitis. Gastroenterol Clin Biol 2007;31:17-25. |
|54.||Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, et al . Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006;21:1448-54. [PUBMED] [FULLTEXT]|
|55.||Joshi S, Cauch-Dudek K, Wanless I, Lindor KD, Jorgensen R, Batts K, et al . Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-13. |
|56.||Angulo P, El-Amin O, Carpenter HA, Lindor KD. Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis. Am J Gastroenterol 2001;96:3021-7. [PUBMED] [FULLTEXT]|
|57.||Poupon R, Chazouilleres O, Corpechot C. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44:85-90. |
|58.||Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36:1393-9. [PUBMED] [FULLTEXT]|
|59.||Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al . Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33:1098-104. [PUBMED] [FULLTEXT]|
|60.||Potthoff A, Deterding K, Trautwein C, Flemming P, Strassburg CP, Manns MP, et al . Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol 2007;45:15-9. [PUBMED] [FULLTEXT]|
|61.||Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartνn P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996;24:308-12. |
|62.||Noel B. Lupus Erythematosus and other autoimmune diseases related to statin therapy:a systematic review. J Eur Acad Dermatol Venereol 2007;21:17-24. |
|63.||Lewis JJ, Iezzoni JC, Berg CL. Methylphenidate-induced autoimmune hepatitis. Dig Dis Sci 2007;52:594-7. [PUBMED] [FULLTEXT]|
|64.||Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al . Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81:488-90. [PUBMED] [FULLTEXT]|
|65.||Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, Aguilera I, Perera-Molinero A, Moneva-Arce E, et al . De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc 2006;38:1467-70. |
|66.||Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al . De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13. |
Lawerence General Hospital, Lawrence, MA 01842
Source of Support: None, Conflict of Interest: None
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9]
[Table 1], [Table 2]
|This article has been cited by|
||Serological markers of autoimmunity in children with hepatitis A
| ||Tawhida Y. Abdel-Ghaffar,Mostafa M. Sira,Ahmad M. Sira,Tahany A. Salem,Ahmed A. El-Sharawy,Suzan El Naghi |
| ||European Journal of Gastroenterology & Hepatology. 2015; 27(10): 1161 |
|[Pubmed] | [DOI]|
||Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity
| ||Raika Jamali |
| ||Thrita Journal of Medical Sciences. 2013; 2(2): 43 |
|[Pubmed] | [DOI]|
| Article Access Statistics|
| Viewed||10179 |
| Printed||353 |
| Emailed||12 |
| PDF Downloaded||2040 |
| Comments ||[Add] |
| Cited by others ||2 |